Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › left ventricular dysfunction

Left ventricular dysfunction

Part of Ventricular Dysfunction

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for left ventricular dysfunction

19 trials tracked for left ventricular dysfunction: 5 in phase 3 or 4 and 1 with published results. The most-cited published study has 76 citations.

19Trials tracked
5Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 3 Phase 3 2 Phase 2 5 Other / NA 9
  1. Phase 3 The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation Completed · 76 cited
  2. Phase 4 Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView. Completed
  3. Phase 4 Effects of Viagra on Heart Function in Patients With Heart Failure Completed
  4. Phase 4 Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone Completed
  5. Phase 3 The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction Completed
  6. Phase 2 Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study) Completed
Show 13 more trials
  1. Phase 2 Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study) Completed
  2. Phase 2 Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study) Completed
  3. Phase 2 A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction Completed
  4. Phase 2 The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT) Completed
  5. N/A Phosphorous Magnetic Resonance Spectroscopy of Heart Completed
  6. N/A PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing Completed
  7. N/A A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System Completed
  8. N/A Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study (Reference # C1918) Completed
  9. N/A IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting Completed
  10. N/A LifeVest Safety and Efficacy in Real Life Settings in France Completed
  11. N/A InterventiOn of Biventricular Pacemaker Function on ventrIcular Function Among Patients With LVAD's Completed
  12. N/A HIS-Purkinje Conduction System Pacing Optimized Trial of Cardiac Resynchronization Therapy Completed
  13. N/A Balloon Pump Assisted Coronary Intervention Study Completed

Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Left ventricular dysfunction: what the trials found

Diagnostic imaging using AdreView (Iobenguane I 123 Injection) demonstrated reproducible myocardial uptake on planar imaging at both 3 hours and 15 minutes post-injection 1.

In clinical management, Captopril was evaluated for its impact on cardiovascular death, hospitalization, and heart failure symptoms over a 9-month period 3. Ivabradine did not show statistically significant differences in primary composite endpoints, cardiovascular death, or hospitalization for acute myocardial infarction 5.

Stem cell therapies showed mixed results regarding cardiac function. One trial of adult stem cells reported no significant changes in global or regional left ventricular function (infarct and border zones) 8, nor did it show significant changes in VO2max, LVESV, or reversible defect size 9. However, a different study of adult stem cells showed statistically significant improvements in global and regional (both infarct and border zone) left ventricular function 10.

Eculizumab was evaluated in the context of heart transplantation, where 18 patients survived at 12 months with zero instances of hemodynamic compromise at 6 months post-transplant 4.

Recent results — preliminary, needs further review

  • Autologous human mesenchymal cells (hMSCs) were studied for effects on serial troponin and creatine kinase values, as well as changes in the MLHF questionnaire score 6.
  • Riociguat was evaluated for changes in pulmonary artery mean pressure and E/A ratios, with results not reaching statistical significance 7.
  • Wearable Cardioverter Defibrillators were assessed in a large cohort 11.
  • HOT-CRT and CRT-D devices were investigated, with the latter showing an improved clinical composite score in 51.3% of subjects at 12 months [12, 13].
  • MR Spectroscopy was utilized to determine heart failure levels based on signal-to-noise ratios 16.

For the clinician treating this condition

  • AdreView provides reproducible myocardial uptake measurements for imaging in heart failure patients 1.
  • Adult stem cell therapy shows conflicting evidence regarding the improvement of global and regional left ventricular function; while one study showed no significant change, another demonstrated statistically significant improvements [8, 10].
  • Ivabradine did not demonstrate a statistically significant impact on cardiovascular death or myocardial infarction hospitalization in the studied cohort 5.

AI synthesis of 11 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Off-pump CABG reduces mortality risk and stroke risk in patients with left ventricular dysfunction
Cardiology Meta-analysis
Off-pump CABG reduces mortality risk and stroke risk in patients with left ventricular dysfunction Off-pump heart surgery shows lower death risk for weak hearts
This meta-analysis of 35,863 patients with multivessel coronary artery disease and left ventricular dysfunction (ejection fraction ≤40%) fou…
A large review of over 35,000 patients suggests off-pump heart surgery may reduce mortality and stroke risks for those with weakened heart m…
Jul 1, 2026
Elective unloading with a microaxial flow pump showed no material difference in outcomes versus standard care in severe left ventricular dysfunction
Cardiology RCT
Elective unloading with a microaxial flow pump showed no material difference in outcomes versus standard care in severe left ventricular dysfunction Heart Pump Strategy Backfires for Weakened Hearts During High-Risk Surgery
This randomized controlled trial enrolled 300 patients with severe left ventricular dysfunction and extensive coronary artery disease underg…
A heart pump meant to protect weakened hearts during surgery may increase death risk for patients with severe heart damage, new evidence sug…
May 7, 2026
Transendocardial ProtheraCytes injections improved physical functioning and vitality in patients with recent large AMI and LV dysfunction
Cardiology RCT
Transendocardial ProtheraCytes injections improved physical functioning and vitality in patients with recent large AMI and LV dysfunction New cell injections help heart patients feel better for six months
This phase I/IIb randomized controlled trial enrolled 31 treated and 12 control patients with recent large myocardial infarction and left ve…
Patients with recent heart attacks and weak heart pumps felt significantly better physically and socially after receiving new cell injection…
May 1, 2026

Research across Ventricular Dysfunction

Related studies from across the Ventricular Dysfunction family.

CABG reduces all-cause death and repeat revascularisation risk in patients with diabetes and CKD
Cardiology RCT
CABG reduces all-cause death and repeat revascularisation risk in patients with diabetes and CKD CABG Shows Lower Risk for Patients with Diabetes and CKD
This systematic review and meta-analysis of 10594 patients with multivessel coronary disease and multiple long-term conditions found CABG fa…
Surgery may offer better outcomes than other procedures for patients with heart disease who also have diabetes and chronic kidney disease.
medRxiv Sep 9, 2026
Anticoagulation associated with lower risk of recurrent stroke in patients with left ventricular systolic dysfunction
Neurology Meta-analysis
Anticoagulation associated with lower risk of recurrent stroke in patients with left ventricular systolic dysfunction Anticoagulants may lower stroke risk for patients with heart dysfunction
This meta-analysis of secondary analyses of randomized clinical trials examines anticoagulation for ischemic stroke prevention in patients w…
New analysis suggests that blood thinners might reduce the risk of both first and repeat strokes in people with specific types of heart musc…
Aug 1, 2026
Statistical Analysis Plan Defines ICD Insertion Based on Ventricular Scar for Left Ventricular Systolic Dysfunction
Cardiology
Statistical Analysis Plan Defines ICD Insertion Based on Ventricular Scar for Left Ventricular Systolic Dysfunction New Heart Scan Strategy May Reduce Sudden Death Risk
This document is a statistical analysis plan outlining methods for a trial involving patients with mild moderate left ventricular systolic d…
A new trial plan tests if heart scans can better decide who needs a life-saving device to prevent sudden cardiac death.
medRxiv Apr 29, 2026
Non-randomized preprint on dapagliflozin and epicardial adipose tissue in HFpEF
Cardiology
Non-randomized preprint on dapagliflozin and epicardial adipose tissue in HFpEF Dapagliflozin linked to fat loss in heart failure patients
This preprint reports a non-randomized clinical trial in 60 patients with left ventricular diastolic dysfunction.
Adding dapagliflozin to standard care reduced epicardial fat in a small group of heart failure patients, though this preprint study needs co…
Apr 28, 2026
Diastolic Age predicts MACE and discriminates LVDD in heart failure cohorts
Cardiology Cohort
Diastolic Age predicts MACE and discriminates LVDD in heart failure cohorts Doctors Can Now Measure Your Heart’s True Age With One Scan
This cohort study involving 1,952 participants from the Project Baseline Health Study, 1,708 from WASE, and 313 from Stanford Cardiovascular…
A new scan tool calculates your heart's biological age to spot hidden risks before symptoms appear, though it is still experimental.
medRxiv Apr 19, 2026